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Abstract Precision Medicine (PM) is an emerging approach that appears with the impression of 
changing the existing paradigm of medical practice. Recent advances in technological innovations and 
genetics, and the growing availability of health data have set a new pace of the research and imposes a 
set of new requirements on different stakeholders. To date, some studies are available that discuss about 
different aspects of PM. Nevertheless, a holistic representation of those aspects deemed to confer the 
technological perspective, in relation to applications and challenges, is mostly ignored. In this context, 
this paper surveys advances in PM from informatics viewpoint and reviews the enabling tools and 
techniques in a categorized manner. In addition, the study discusses how other technological paradigms 
including big data, artificial intelligence, and internet of things can be exploited to advance the potentials 
of PM. Furthermore, the paper provides some guidelines for future research for seamless implementation 
and wide-scale deployment of PM based on identified open issues and associated challenges. To this 
end, the paper proposes an integrated holistic framework for PM motivating informatics researchers to 
design their relevant research works in an appropriate context. 
INDEX TERMS: Precision Medicine; Bioinformatics; Informatics; Artificial Intelligence; Internet of 
Things; Big Data; Clinical Decision Support; Deep Learning; Machine Learning. 
I. INTRODUCTION 
Precision Medicine (PM) is one of the fledging paradigms 
that the next generation healthcare solutions sprouting 
towards. It helps us grow more knowledge on human 
physiology by means of genomic insights and advances in 
technology. PM is an attention-grabbing area of research 
for medicinal community with various multidimensional 
prospects. At the same time, it is quite exciting for 
informatics community with enormous potential to 
research and exploit the technological perspective for the 
common goals. It is however challenging for either 
community to absorb the technicalities involved in 
drawing relationships among different prospects in this 
cross-disciplinary research field. From informatics 
viewpoint, PM introduces a new level of challenges on the 
developing informatics solutions including omic 
informatics and health informatics for a more focused and 
precise patient care. 
A. BRIEF OVERVIEW OF PRECISION MEDICINE 
The concept of PM emerged as a healthcare-aligned 
mainstream discipline through its formal launching in 
2015 as the prevention and treatment that consider the 
individual variability [1]. To put it simply, PM refers to 
serve the right patient with the right drug at the right time, 
by considering the molecular events that are accountable 
for the disease [2]. The term precision medicine is often 
muddled with personalized medicine [3], [4] due to the 
inclusion of the word “Individual” in the definition of the 
PM itself.  However, the PM provides a more 
comprehensive and precise meaning to what 
individualized and personalized medicine were 
representing over the years. Unlike personalized 
medicine, the notion of PM is to combine clinical data 
with population-based molecular profiling, 
epidemiological data and other data so as to make clinical 
decisions for the benefit of individual patients [5]. The 
personalized medicine terms is used dominantly in some 
regions of the world and in a commentary, the authors 
termed PM as a part of personalized medicine [6]. The 
other terms they mentioned include “individualized 
medicine,” “genomic medicine,” “stratified medicine,” 
“pharmacogenomics,” and “P4 medicine”. This study, 
however, uses the term “precision medicine” as a main 
subject in the search queries and focuses on the same in 
the contents to avoid any confusion with other competitive 
terminologies. 
The paradigm shift to PM from the traditional medicine 
approaches can be thought of as a movement from 
generalization to personalization. In other words, unlike 
the current approaches that consider a general 
understanding based on the average conditions and 
clinical outcomes for the patients of interest, the PM 
approach works based on the individual variability in 
genes, environment, and lifestyle [4]. Consequently, 
whereas current approaches might be successful for one 
group of patients and not for the other, PM-based 
approaches are more likely to be effective for each group 
of patients. The abstract level comparison of PM with 
current approaches is depicted in Figure 1. The schematic 
shows the key differences between traditional and PM 
approaches in terms of classification of patient population 
– whereas PM classifies the patients based on risk and 
identifies the surveillance for preclinical disease, 
conventional approaches look for the signs or symptoms 
and deal the patients equally if they share the same 
symptoms [7]. Because of this generalization, in 
conventional approaches the benefits are not reached out 
to all the patients; however, in PM, each group of patients 
get equal level of benefits as they are treated rightfully 
with the right treatment. 
The PM approach attracts multiple stakeholders in the 
biomedical enterprise, including care providers, payers, 
researchers, and patients [8]. Also, it seeks for the 
integrated expertise on the different but interrelated 
domains including, to the minimum, physicians, 
biologists, and computer scientists. It is clear that two 
aspects of participation in PM are taken of utter 
importance: (i) the healthcare system in order to deliver 
precise diagnosis and therapies and (ii) the scientists to 
develop the infrastructure, principles, and insights into PM 
[9]. 
B. STUDY OBJECTIVE AND CONTRIBUTIONS 
In this study, we explore an informatics perspective of PM 
describing principles, issues, challenges and prospective 
solutions. Moreover, we include different initiatives 
around the world on the subject and a historical journey to 
create a case for bridging the current evidence-based 
medicine (EBM) with PM. The existing studies [8][10] 
provide a big picture of an informatic research and 
envision the need of advanced tools and technologies to 
support PM. Also, we can find a fair set of literature 
[11][12] that discuss about the PM realization and 
implementation issues and challenges. The larger set of 
existing studies is available on the molecular and -omic 
information in terms of efficient algorithms and methods 
for genome mapping, alignments, variant callings, and 
annotations.  Similarly, the clinical aspect has been 
researched and implemented in the long run without 
aligning the focus to consider the other aspects of PM - 
genome and environmental data. Moreover, PM is 
recognized as tantamount to a technology-driven approach 
FIGURE 1. Traditional and PM approaches with key differences on classification factors and treatment 
outcomes. 
[13], therefore, it embroils algorithm and technology in its 
meaning. 
This study provides an overview of existing efforts on PM 
informatics agenda, tools and techniques in three areas of 
informatics – bioinformatic, clinical informatic, and 
participatory health informatic, security, standardization, 
integration, and implantation challenges, and the design of 
holistic PM framework to enlighten the futuristic 
endeavors in the area of informatic research and 
implementation. In this regard, the contributions of this 
paper are outlined below: 
• To encourage the principle of ‘learn to exist’ 
rather than to compete, this study compiles the 
state-of-the-art views on PM to achieve a 
pragmatic balance among the existing 
approaches. The study adds on the 
reconciliation strategies between the existing 
evidence-based medicine (EBM) and emerging 
PM approaches. 
• To cover an inclusive picture of PM from tools 
and technologies perspective, we elaborate and 
generate a comprehensive summary of 
prominent programs, tools, frameworks, and 
platforms in three aspects of informatics: 
bioinformatics, clinical informatics and 
participatory informatics.  
• The lifelines of PM- Big data and artificial 
intelligence (AI) are included and elaborated in 
the study to draw a useful relationship model 
with PM. 
• The internet of things (IoT)-enabled healthcare 
has potentials to be a part of PM. In this context, 
we briefly discussed advantages of IoT-aided 
PM and presented a conceptual model that 
integrates both the paradigms. 
• The study analyzes the implementation 
challenges of PM and highlights the design 
issues of clinical decision support systems. It 
takes into account the integration and 
standardization challenges in terms of data 
privacy, safety, security, and exchange 
standards for interoperability, and issues of 
realization and design of an ecosystem for PM. 
• Based on identified limitations on PM 
implementations, we propose a holistic 
integrated PM framework that assists computer 
scientists, health- and bio-informaticists to carry 
forward the challenge of successful realization 
of PM.  
C. LITERATURE SURVEY METHODOLOGY 
Objectively, we employed the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta 
Analyses) [14] method for literature survey based on the 
process followed in [15] with additional customizations in 
the inclusion/exclusion criteria. We ran search queries on 
two search engines viz. Web of Science and PubMed and 
linked all the search results into a local repository. A bulk 
of peer-reviewed articles are checked for duplication and 
the abstracts are screened to exclude all those articles that 
are focused either on biology, molecular and/or clinical 
perspective or unavailability of the full-text documents. 
The rest of the articles are checked for eligibility criteria 
to include articles focusing on the topics noted earlier with 
PM as a primary content. It should be noted that some of 
the articles are cited just for general reference on the topic 
FIGURE 2. PRIMA flow diagram for literature survey of the articles included in the study. 
even though the central content therein is not PM. For 
example, [16] that talks on IoT in healthcare is a topic-
oriented citation rather than a PM-focused citation. 
Similarly, we also referred to few popular websites and 
blogs, particularly, where the contents were of 
introductory nature such as PM global initiatives. The 
Figure 2 explains the steps taken in the entire literature 
survey process. The number of articles excluded at 
different stages and the final set of articles included in the 
study are explicitly mentioned. 
The rest of the paper is structured as follows. Section 2 
describes the need of bridging the gap between EBM and 
PM. Section 3 explains the enabling tools and techniques 
of PM. Section 4 is dedicated to discuss the Big Data and 
AI in PM followed by section 5 that highlights the role of 
IoT in PM. Section 6 analyzes the implementation 
challenges while section 7 focuses on the global initiatives 
regarding PM. In section 8, we provide the future direction 
and presented our proposed integrated framework for PM. 
The final section concludes this systematic survey.  
 
II.  BRIDGING EBM AND PM 
EBM has long been utilized in healthcare environment to 
serve different purposes like supporting clinical decisions, 
medical education, and health awareness. According to the 
comprehended definition described in [17], EBM is the 
use of evidence collected from well-made research  
formulated in primary studies such as meta-analyses, 
systematic reviews, and randomized controlled trials used 
for improved decision-making in medicine. In this way, 
EBM approximating the “one size fits all” implies the 
scenario of applying to all although it may not be exact 
from the perspective of EBM proponents. As we learned 
in the preceding section, PM focuses mainly on the 
individualistic behavior, a deviating scenario from the 
EBM. As shown in Figure 3, there also exist differences 
between EBM and PM in terms of the basic elements in 
decision-making process. However, both share similar 
characteristics on multiple grounds. In an editorial, 
authors opinioned that EBM and PM can be more 
advantageous if they can adopt the principle of ‘learn to 
exist’ in a symbiotic relationship to attain a pragmatic 
balance between them [18]. 
They further hinted to an important factor of bridging the 
two paradigms – if we fail to do so it might turn out with 
non-integrable outputs to address the health requirements, 
they originally set out to address. Similarly, authors 
concluded in their study [19] that EBM and PM 
complement rather than oppose one another although 
these approaches have their own merits and shortcomings. 
However, the efforts to reconciling EBM and PM demand 
a clear understanding of the fundamental differences 
between them. We investigate the differences and 
similarities between EBM and PM and present the 
findings in Table I. 
The co-existence of EBM with PM amid the differences 
mentioned in Table 1 raises several challenges in terms of 
volume, format, and structure of data. We turn out few of 
the challenges that are certainly required to be sorted out 
making the amalgamation of EBM and PM a success. In 
Table II, some of the challenges are presented with 
tentative solutions with the aim of bridging the two 
paradigms.
  
FIGURE 3. The decision-making basic elements of EBM in (a) and PM in (b); which indicates that all the elements in (a) are included in (b). 
TABLE I  
SIMILARITIES AND DIFFERENCES BETWEEN EBM AND PM
Similarities 
• Both EBM and PM have the objective of providing better decision on patient health problem. 
• Both demand high quality and reliable evidence for the care of patients. However, the meaning of evidence 
could be different in two paradigms. 
• Respecting patient in terms of either preferences or lifestyle is a part of both EBM and PM decision-making 
basic elements. 
Differences 
• EBM projects “one size fits all” approach and does not provide adequate solution for outliers. By contrast, PM 
deals with the outliers and projects the idea of “one size doesn’t fit all” scenario [20]. 
• EBM is cognitive-biased on occasions where clinicians set the goal and question for the trials and may favor 
the publication based on reputation, the product of manufacturer who funds the study to be conducted [21], 
[22]. PM, on the other hand, relies on patient information that are existed rather than to rely on hypothesis only. 
• Since EBM relies on RCTs, outcome of RCTs are received in the form of either benefit, no effect, or adverse. 
In case of PM, the outcomes shall always be beneficial because they are target oriented that may leads to invent 
a new drug for the treatment [23].   
• EBM over-emphasizes the clinical consultation and is mainly concerned about the people who seek care. It 
underestimates the power of social networks where people can inform each other about their health problems 
[24]. Since it focuses on individual preferences, PM thus encourages the emerging ways of data curation from 
diverse sources. 
 
TABLE II 
CHALLENGES AND POTENTIAL SOLUTIONS OF RECONCILING EBM AND PM 
Challenges Prospect solution 
• Analysis of voluminous data resided in different 
databases  
• Bringing together data of various formats such as 
clinical and molecular. 
• Lack of standardization of data entry and storage 
• Understanding the paradigm shift from therapy to 
prevention, thus ultimately leading to clinician-to-
patient communication and citizen-centered 
healthcare [25]. 
• Current published research has minimal patient input 
[24], thus it requires to include larger patient input in 
the future publishing. 
• The proponent experts from both EBM and PM 
paradigms need to form a consortium/body to 
construct a unified architecture on the common 
grounds to revise the basic elements of clinical 
decision making. 
• Revisions and update of the guidelines of 
developed for EBM, for instance, the criteria of 
RCTs structure, conducting, and evaluations. 
•  Devising a method to include patient input in the 
future research publishing.  
III. PM Enabling Tools and Techniques  
Precision Medicine introduces a new level of challenges for 
developing informatics solutions including –omic 
informatics and health informatics for a more focused and 
precise patient care. The informatics solutions range from 
data curation to processing, interpretation, integration, 
presentation, and visualization. The need for such enabling 
informatics solutions have been realized and discussed in 
array of studies [2], [26]–[30] with a central point of 
requirement of tools and techniques for voluminous, 
complex, and heterogeneous data processing, integration, 
and interpretation as well as knowledge acquisition and 
sharing. In order to describe the diverse set of PM enabling 
tools and techniques, we classify the tools in Figure 4 based 
on three areas of informatics: bioinformatics, clinical 
informatics, and participatory health informatics.  
A. Bioinformatics Tools  
Bioinformatics refers to the establishment of an 
infrastructure to provide means for storing, analyzing, 
integrating, and visualizing large amounts of biological data 
and related information and providing access to it using 
advanced computing, mathematics, and different 
technological platforms [31]. The term ‘big data’ resonates 
in the contents while talking about bioinformatics because 
big data technologies are required to process and analyze 
large genomic data sets [32]–[34]. Several tools are 
designed to work on genomic data at different levels. For 
instance, GMAP (genomic mapping and alignment 
program) [35] is a tool for next generation sequencing with 
a key functionality of sequence mapping and is designed to 
work on genomic, transcriptomic, and epigenomic data. 
Other similar tools used for –omic data processing, 
searching, and alignments include BWA (Burrows-Wheeler 
aligner) [36], STAR (spliced transcripts alignment to a 
reference) [37], GATK (genome analysis toolkit) [38], 
BLAST [39], DIAMOND [40] and others. The 
OmniBiomarker is a web-based application developed for 
biomarker identification that utilizes a curated knowledge 
base of cancer-genomic for analysis of high-throughput 
data [41]. Similarly, a number of tools are available for –
omic data modeling such as, CODENSE (coherent dense 
subgraphs) [42], MEMo (mutual exclusivity modules in 
cancer) [43] and WGCNA (weighted correlation network 
analysis) [44]. The leading tools available for the molecular 
and biological data analysis among others are Geneious 
Prime [45], Cytoscape [46], [47], and Gephi [48]. There is 
a cloud-based integrative bioinformatics platform for 
precision medicine called G-Doc Plus for handling 
biomedical big data using its cloud computing resources 
and other computational tools [49]. On top of that, there 
exist a few other language-specific tools, libraries, and 
software packages in bioinformatics such as BioJava [50], 
BioPHP, BioPerl [51], PioRuby [52], and BioPython [53].  
B. Clinical Informatics Tools 
Clinical informatics is a subfield of health informatics, 
which focuses on the usage of information in support of 
patient care [54]. Over the last two decades, clinical 
informatics has progressed with an array of tools and 
techniques including computerized entry systems, 
analytical tools, decision support tools, and other clinical 
reporting techniques appeared to assist healthcare 
professionals in different aspects. One of the related areas 
in clinical informatics is clinical information extraction, on 
which a significant volume of research had been conducted 
over the years. A methodological review [55] reported a 
wide range of information extraction frameworks, tools and 
toolkits including cTAKES [56], MetaMap [57], MedEx 
[58] and others. Another related aspect of clinical 
informatics is healthcare data analytics. The analytics area 
itself is huge and we do not necessarily aim to cover every 
aspect of it. However, the popular tools and techniques that 
focused on clinical aspects of the medical data are 
discussed. This is to emphasize that healthcare data analysis 
area is not limited to clinical data analysis rather it 
FIGURE 4. Classification of enabling tools and techniques in three areas of informatics: clinical 
informatics, biomedical informatics, and participatory health informatics 
encompasses the combined analysis of phenotypes and 
genotypes. Data science tools in general have been used at  
the same pace and importance as of clinical data analysis. 
For instance, RapidMiner [59] and KNIME Analytics 
Platform [60] are the leading data science tools that are 
equally applied for clinical data analysis.  
C. Participatory Health Informatics Tools 
PM expands the scope of medical care as most of the 
population spends more time outside than the time in the 
physician’s office. It demands a deeper consumer 
participation to collect information about a person’s 
lifestyle and environment e.g. physical activity, dietary 
information, sleeping patterns, and other environmental 
conditions [8]. A significant number of systems and 
applications is added to the portfolio of quantified-self 
programs and digital health in recent years due to the 
increasing trends in wearables and mobile technologies 
[61]. Mining Minds (MM) project, is aimed at developing a 
novel framework for mining individual’s daily life data 
produced from diverse resources [62]. The objective of the 
MM project is in line with other endeavors such as Google 
Fit [63], Samsung Health [64], Fitbit [65], and Noom [66]. 
However, it is more comprehensive and novel in terms of 
knowledge acquisition and context-aware personalized 
knowledge-based service support. Currently, these tools 
and services are geared towards nursing user health status 
for physical activities, diet, and somewhat sleep patterns 
and as well as the environmental factors. In the era of PM, 
it is required to channelize such efforts in a way to supply 
consumers' health monitoring and environmental 
information to their respective health providers for assisting 
in decision making. The genomic information could better 
be interpreted with this information and it will thus assist 
the physicians to precisely diagnose a disease and treat. 
There is a lot of other platforms and frameworks which 
cannot be put in a specific category rather then they are 
enablers for data analysis such as platforms for big data 
analytics including Apache Hadoop (MapReduce) [67] and 
IBM Infosphere Platform [68]. A selected list of tools for –
omic data processing and biomarker identification is 
provided in a study on -Omic and EHR Big Data Analytics 
for Precision Medicine [29]. 
D. Summary of PM Enabling Tools and Techniques 
The prominent tools and platforms to support PM in data 
processing, analysis, interpretations, sharing, and 
visualization reported in various studies are available under 
public and commercial licenses.  It is important to note that 
some of the available platforms and tools are domain 
independent and are used for data analysis of any domain. 
For instance, the RapidMiner Studio [59] is a cross-platform 
data science tool, clinical informaticians use it for clinical 
data analysis and very recently, bioinformatics tools start 
integrating it in their workflows for enhanced data mining, 
analysis, and visualization.  
 
IV. Big Data and Artificial Intelligence  
In medicine, the application of AI has two divisions: virtual 
and physical. Whereas the former is characterized by 
machine learning (ML) and/or deep learning (DL), the latter 
comprises physical objects, medical devices, and 
sophisticated robots [69]. In fact, the use of big data and AI 
is a central aspect of PM initiatives [70] and some even 
phrased it “there is no PM without AI” because of its 
fundamental requirement of computing power, algorithms 
machine learning and deep learning), and intelligent 
approaches that uses the cognitive capabilities of physicians 
on a new scale [71]. Deep learning has been widely used for 
clinical information extraction, phenotype discovery, image 
analysis, and next generation sequencing [72], [73]. AI 
upsurges learning abilities and offers decision-making 
capabilities at a scale to transform the healthcare future [74]. 
Therefore, physicians in everyday practice get pressure to 
look around innovations spreading over faster than ever 
through the use of disruptive technologies and exponential 
growth of healthcare data- the “Big data” [75]. Big data has 
gained a growing attention from data-oriented enterprises in 
private and governmental sectors [76]. Despite the fact that 
we are living the in the age of big data, however, the big 
data by itself is of no use without the processing using AI 
techniques which make it useful thus brings the potential to 
transform the current clinical practice [77]. AI techniques, 
such as applications of machine learning on big data, are 
changing the way physicians make clinical decisions and 
diagnosis. Big data analytics using PM platforms has 
therefore the potential to include data of millions of patients 
for exploration and validation [77]. It is of more importance 
to understand interrelationships among big data, AI (ML 
and DL), and the PM. Developing a PM platform or relevant 
tools and services requires access to big data and processing 
(big data needs AI approaches including ML and DL 
variants. Figure 5 illustrates the relationship of big data and 
AI in PM derived from the illustrations presented in [70], 
[77]. 
Many technology companies including IBM with a flagship 
platform of IBM Watson, Google with DeepMind, and 
others such as Apple and Amazon, are investing heavily in 
health care analytics to facilitate PM [70], [71], [77]. 
Despite the facilitation and improvements powered by AI 
for genomic and other omic data processing and analyzing, 
there still exist various challenges. In a review [78], authors 
focus on AI applications of next generation sequencing and 
cancer genomics testing required for PM. In Table III, we 
gathered a set of key benefits of AI in the era of PM and the 
associated challenges. 
 
 
 
   
   
 
 
TABLE III 
KEY TOPICS WITH BENEFITS ON THE LEFT (GREEN ICONS) AND CHALLENGES ON THE RIGHT (RED ICONS) 
Key benefits of AI in PM Challenges 
  
 
 
 
 
 
 
V. Role of IoT in Precision Medicine  
The internet of things (IoT) enables us to introduce 
automation in nearly every field and healthcare is one of the 
most important and attractive application areas of this 
auspicious technology. The IoT uprising is reshaping 
modern healthcare with propitious technological, 
economic, and social prospects. The role PM plays can be 
further enhanced by integrating the IoT. 
As noted in the early part of this paper, PM primarily 
involves three categories of data – clinical data, genome 
data, and environmental data. On the other hand, a simple 
and brief description of how an IoT-based healthcare 
system works can be presented as follows. First, the IoT 
medical sensors and devices directly connected to the 
patient's body of interest. Sensors collect various 
physiological conditions and vitals. Accumulated data are 
 FIGURE 5. Illustration of relationship between big data, artificial intelligence, and precision medicine 
Variant calling 
 AI algorithms leveraged to 
enable variant calling from 
NGS data. 
 AI algorithms are utilized 
for entity and relation 
extraction from published 
literature. 
Literature Mining 
 AI algorithms are used to facilitate 
the process of variant classification 
and to ease manual curation. 
Variant interpretation and reporting 
Ground truth scarcity for validation of benefit 
 Obtaining statistically significant patient 
outcome data is challenging. 
Transparency and reproducibility 
 Companies, platforms, and publications offer 
limited information for public consumption. 
Patient / physician education 
 Both patient and physicians should get 
precision medicine related education to 
enjoy the outcomes brought by AI and big 
data. 
preprocessed and organized and are subsequently analyzed. 
The data are stored in the associated medical service 
provider's cloud storages for aggregation. Depending upon 
the analytics and aggregation results, patients can be 
monitored from distant places and necessary actions are 
taken following predefined standard rules and guidelines. 
Interested readers are referred to the compressive study 
reported in [123] to grow more knowledge on the IoT-based 
healthcare. Clearly, the IoT can prominently assist PM by 
arranging the environmental data in an automated fashion 
because the participating health data is mostly collected by 
physical sensors and actuators. In addition, a dedicated 
intelligent coordinator can exploit the cross-sectional data 
consisting of IoT-provided data and clinical/genome data. 
Here we present an overview of several possible avenues of 
integrating the IoT with PM. 
A. Risk Minimization in ADR 
The IoT can play a significant role in mitigating the risk 
associated with adverse drug reaction (ADR) [123]. In 
layman's terms, an ADR is an undesirable or injurious 
response experienced following the administration of a 
drug or combination of drugs under natural conditions of 
use and the suspicion of the unwanted response is held 
accountable mostly to the drug/s administrated [40]. A 
substantial number of admissions to hospital are caused by 
ADRs and hospitalized patients often experience ADRs 
that muddle and extend their stay. Many of the ADRs can 
be avoided if the appropriate care is taken. An ADR will 
usually require the drug to be discontinued or the dose 
reduced. For example, a simple sensing system can detect 
whether the dose or plasma concentration has risen above 
the therapeutic range. Such a concept of an IoT-based 
ADR is found in [74]. The work makes use of barcode or 
NFC-enabled devices so that the patient side recognizes 
the drugs. Then, an AI-based pharmaceutical system 
senses and analyzes the patient's health and molecular 
profiles. Eventually, the system performances matching 
comparison to conclude whether the suggested drug is 
well-suited. In a normal clinical viewpoint, the nature of 
ADR is characteristically generic i.e., not medication-
specific for a particular disease. Therefore, a generic 
software package termed ADR services is required. The 
ADR services is supposed to cover certain mutual 
technical issues and their generic solutions [123]. 
However, the ADR services to be used in PM should be 
further customized and fine-tuned to cover the respective 
PM cohort. 
B. Safe and Secure Medication 
The safety of the medicine in PM is one of the unique 
challenges that must be addressed by the pharmacists [79]. 
Also, the need for an entirely connected and transparent 
global healthcare supply chain will continue to grow and 
this is where the IoT can be useful. The IoT devices can 
monitor a bunch of parameters, including location, 
temperature, light exposure, humidity, as well as security 
to guard against theft and forging. Although this sort of 
supply chain control and monitoring is important for all 
industries, it is more vital for healthcare industry in 
general and PM in particular. For example, it will not be 
possible to have a quick substitute when a shipment of 
medicine that is personalized for the DNA of a patient with 
a life-threatening illness is spoiled or stolen. 
C. Medical Error Minimization 
The main objective of PM is to delivery of optimized 
targeted stimulation. This is optimized, in the sense that 
the therapy is tailored to individual patients. The targeted 
stimulation does not allow a medication (e.g. taking a pill) 
to be metabolized throughout the patient's body. Instead, 
it stimulates the intended target in a controlled manner, 
and thereby reducing any side-effects. With the use of 
medical IoT devices, it is possible to steer the stimulation 
to a particular target with a much higher degree of 
precision [80]. As experienced in any system, the 
occurrence of medical error in healthcare in general is also 
affected by a several factors. With the introduction of PM, 
this error margin increases exponentially because of 
modular clinical treatment approaches. For example, 
caregivers (e.g. hospitals) are usually at over-capacity and 
thus they face scalability issue to increase access to care. 
Co-morbidity supervision becomes even more difficult 
than before. To address this issue, we can establish an IoT-
based health network for an automatic patient caring 
process [81]. 
D. Automation in Gene Expression Measurement 
Gene expression profile has widely been used to uncover 
the association of environmentally-swayed or disease 
phenotypes with the mRNA expression patterns [82]. Due 
to its incredible application in computable genotyping, 
genetic variation of inter and intra organisms, early 
finding of disease, polymerase chain reaction (PCR) [83] 
and its subsequent derivatives are widely used to obtain 
real-time gene expression profiling. Then, because of 
rapid progress in miniaturized electrochemical DNA 
biosensors, it is possible to generate transformed 
electronic signal from the sensitive bio-receptor through a 
transducer (e.g. photo counter) in an automatic process, 
calling the need of an IoT-based health network, with a 
minimum involvement of technical personals in the close 
loop system. The system as a whole can eventually assist 
PM to predict disease risks and even what foods to 
consume based on patients' genome and extracted 
physiological sensors data [84]. 
The PM basically provides customized healthcare 
solutions to the individual cohort of patients. With the help 
of IoT, this customization itself can be improved by 
learning the individual's concerned physiological 
functions. For example, one can consider a possible way 
to improve the symptoms of a Parkinson's disease patient 
through a better deep brain stimulation (DBS) therapy 
using IoT (Figure 6). 
DBS is a neurosurgical procedure which uses a 
neurostimulator that delivers electrical stimulation, 
through implanted electrodes, to specific targets in the 
brain for the treatment of neuropsychiatric disorders [85]. 
To advance the DBS therapy, we need to understand how 
individual's brain works. By sensing signals from the 
brain, we can learn more about how brain responds to the 
therapy.  Low field potential (LFP) recording is promising 
to enable detection, measurement, and collection of brain 
signals [86]. The collected LFP signals along with other 
medical sensors data can then constantly be analyzed to 
improve the targeted DBS therapy [80]. This technology 
would eventually enable a precise adjustable algorithm 
which could lead a better understanding about various 
overwhelming neurological problems. 
E. Summary and Insight  
Digital innovations collectively appear as a paradigm 
changer of how healthcare organizations provide quality 
patient services with enhanced clinical satisfaction while 
maintaining a safe and secure environment at each stage 
associated with the ecosystem. In line with that, IoT can 
potentially be integrated with PM to achieve improved 
automation in general. In particular, the IoT-enabled PM 
is potential to offer several benefits such as real-time 
monitoring of adverse drug reactions and secured 
healthcare supply chain. Even, IoT can be utilized to 
design innovative personalized therapies e.g., IoT-aided 
personalized DBS therapy, conceptualized in the early part 
of this section. 
 
VI. Implementation Challenges 
In this section, we discuss more of the design challenges 
of futuristic PM system and services such as clinical 
decision support systems, ecosystem, and the challenges 
exist in in the integration and standardization of data 
elements and processes. 
A. Redesign of Clinical Design Support 
Computer-based clinical decision support (CDS) are 
meant to enhance the decision-making capabilities by 
utilizing the individual-specific information and clinical 
knowledge [87]. It serves to facilitate different stakeholder 
like physicians, nurse, patients, and others in making 
effective clinical decisions. Formally, a CDS is referred to 
“a process for enhancing health-related decisions and 
actions with pertinent, organized clinical knowledge and 
patient information to improve health and healthcare 
delivery” [88]. Historically, the CDSs delivered promising 
results in diverse systems and services such as the 
reminder systems, the drug dosing and drug-drug 
interactions, the diagnoses and treatment, and the pharma-
related fields [89]–[91]. Despite its potentials in 
improving health and healthcare, CDS has several 
challenges to accomplish its full promise [92]. Moreover, 
the fresh developments in the medicine domain and the 
presence of disruptive technologies pose a new set of 
challenges to develop models for CDS. This led us to put 
question to ask, do we need to rethink about the CDS’s 
design in order to build a practical model for the PM era?  
The answer is certainly positive based on the realization 
by the researchers in their research works [8], [91], [93], 
where they pointed out the need of a CDS design that 
encompass a more comprehensive knowledge base (KB) 
to fulfill the key requirements of PM. Contemporary CDSs 
serve a fraction of clinical care whereas a common 
decision in PM shall require accumulating data from 
different components that are not integrated at one place. 
Researchers working in the area of informatics to advance 
PM [8] stressed upon the designing of an all-inclusive KB 
comprising information about disease subtypes and risks, 
diagnosis, treatment, and prognosis. Nevertheless, the 
available KBs are isolated from each other and are thus 
unable to provide support for executing the federated 
queries. On that, in addition to flexibility and scalability, 
the KBs need to be revamped to support not only the 
FIGURE 6. A conceptual model of an IoT-aided personalized DBS therapy. 
federated queries but also an extended reasoning 
capability. In a study [91], authors pointed-out the data 
isolation issue by highlighting the fact that the two sets of 
data, clinical and scientific, are typically placed in 
different repositories as information silos. They need to be 
linked and presented in a way that clinicians and other 
researchers can easily interact and review. This raises the 
requirement for a standard language and algorithm for 
executing a federated query. The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) 
Informatics Working Group is developing a standard 
guidelines for the effective implementation of 
Pharmacogenetics in the day-to-day medical care [94]. 
This group also uncovered the limitation of present-day 
CDS issue of addressing single gene by relying on local 
versions of national guidelines. The group emphasized to 
step-forward to a national implementation by designing 
and implementing futuristic resources. 
We summarize the core limitations of the contemporary 
CDSs in Table IV. Addressing these limitations while 
redesigning the CDSs in the era of PM, raises to a few 
challenges to consider for their resolution. In a study [89], 
we envisioned the conceptual architecture of the futuristic 
CDS eligible to support the functional requirements of PM 
services. In contrast to contemporary architectures of 
CDSs, the futuristic CDS model incorporates the modules 
of supporting federated queries, a supervisor KB that 
holds the information of disease subtypes and risks, 
diagnosis, treatment, and prognosis. 
TABLE IV 
 LIMITATIONS OF CURRENT CDSS WITH CHALLENGES AND PROSPECT SOLUTIONS. 
 
  
Current CDSs Limitations Challenges Prospect Solutions 
The knowledge bases of 
contemporary CDSs are isolated 
from one another and they are 
unable to support federated 
querying [8].  
How to design a comprehensive 
KBs to integrate information about 
various features such as disease 
subtypes, disease risk, diagnosis, 
therapy, and prognosis. 
• Allowing data sharing and consensus on clinical 
interpretations and multiscale data. 
• Enabling effective ontological modeling, knowledge 
provenance, and maintaining the integrated KB. 
• Utilizing a set of novel computational reasoning approaches 
to allow efficient federated queries. 
Isolation between scientific and 
clinical data [91]. 
How to establish a meaningful 
connection between patient data 
and primary literature when the 
EHR databases are considered as 
information silo themselves? 
• Applying standard vocabularies and data formats to 
integrate disparate data sources.  
• Developing new research platform with a set of methods and 
tools to enable analysis and visualization of not only a 
massive amount of raw data generated in clinical set ups, but 
also the data resides in different databases of biomedical 
literature. 
 
B. Design of PM Ecosystem 
As noted above, we briefly mentioned about the three core 
aspects of informatics (i.e., bioinformatics, participatory 
health informatics, and clinical informatics) with their 
basics and provided information on selected set of tools 
and techniques. Nevertheless, it is also important to 
discuss the informatics solutions for PM which requires a 
holistic overview of working together as outlined below: 
• Curation of data generated via participatory health 
using mobile devices, sensors, social media, and other 
IoT devices as well as environmental factors’ data at 
a point of care for the assistance of genomic data 
interpretation which ultimately could help in precise 
patient care.  
• Creating a synergy between bioinformatics and 
clinical informatics by developing infrastructure, 
tools, techniques and applications that bridge the two 
areas and allowing the sharing of data to offer 
integration of individual patient data into the clinical 
research environment [95]. 
• Development of a comprehensive framework that 
facilitates tools and techniques to integrate, process, 
and analyze data curated from diverse sources in all 
three areas; clinical, genomic, and lifestyle & 
environmental factors to enable one-point decision in 
a precise manner.  
• Development of a coherent framework for dealing 
with multi-scale population data including the 
phenome, the genome, the exposome, and their 
interconnections [96]. 
A series of efforts have been made to provide informatics 
solution to support PM in a comprehensive manner. For 
instance, the network ENIGMA (Evidence-based network 
for the interpretation of germline mutant alleles) [97] is an 
international consortium for assessing clinical 
significance and risk related to sequence variation in 
genes, BRCA1 and BRCA2, which currently include over 
100 research scientists and clinicians from 19 different 
countries. Similarly, ClinVar [98], an archive partner of 
ClinGen project is an archive (freely available) for 
variants’ clinical significance interpretations. National 
Center for Biotechnology Information (NCBI) has 
provided an explorer tool to facilitate identification of 
clinical significance discrepancies in ClinVar [99]. In one 
of the reports [11] there is given a set of fundamental 
aspects of PM and describes the key aspects of 
computational infrastructure built on clinical-grade 
genomic sequencing. Authors therein emphasized on the 
integration of PM program into a medical institution’s 
clinical system to facilitate billing and reimbursement. 
The proposed PM infrastructure integration with existing 
electronic health record infrastructure is shown in Figure 
7. The existing EHR infrastructure depicted on the left is 
integrated with PM infrastructure on the right through 
passing the patient specimen information to the laboratory 
information management system (LIMS) in order to 
process, sequence, and analyze the specimen data. The 
LIMS component of the PM infrastructure sends back the 
report formed over the specimen data to the pathology 
system of the EHR infrastructure. 
C. Integration and Standardization 
For successful data integration and exchange, data and 
metadata standards are required. However, there are 
several issues to achieve this goal in terms of either 
lacking of such standards or inconsistent use of existing 
standards, particularly in “omics” domain [8]. Prior to 
frame these issues for discussion, we first describe the 
meanings of what constitutes a ‘data standard’ in order to 
avoid confusion as different groups and individuals have 
different definitions for standards. According to the 
International Organization for Standardization, a standard 
is, ‘… a document that provides requirements, 
FIGURE 7. Components of an integrated precision medicine workflow illustrating existing HER and novel PM infrastructure- (QC: 
Quality Control) 
specifications, guidelines or characteristics that can be 
used consistently to ensure that materials, products, 
processes and services are fit for their purpose’ [99].  
There is further division in standards as data standards for 
integration and exchange and data standards for security, 
privacy, and integrity, covered as one of seven key areas 
in the research work [8]. The research emphasized on the 
need of extending the scope of the existing standards 
rather to invent a new. For that, the individuals or 
organization seek to adopt an existing standard should 
work closely with the owner of that standards to extend 
the scope. Not only co-working, relevant stakeholders 
should focus on outreach and education/training to 
educate the potential adopters of understanding and using 
existing data standards. Data standardization for 
integration and exchange is required for correct 
interpretation of the data elements. The motivation for 
data standardization on security and privacy comes from 
the notion of developing mutual consensus on the level of 
data as well as the protocol definition for sharing. 
A number of initiatives have been taken place to facilitate 
the adoption of data standards especially in the ‘omics’ 
discipline. One of these initiatives is BioSharing that 
works to ensure the standards are searchable and 
informative by mapping the landscape of community 
developed standards in the life sciences including 
biomedical sciences [100]. BioSharing facilitates those 
who are looking for information based on the existing 
standards, finding duplications or gaps, encourage 
harmonization to avoid reinvention, and developing 
criteria items for evaluating standards for adoption. The 
American College of Medical Genetics and Genomics 
(ACMG) together with Association of Molecular 
Pathology (AMP) and College of American Pathologists 
members formed a workgroup with the goal of developing 
a classification of sequence variants using criteria 
informed by expert opinion and empirical data [101]. This 
workgroup is aimed at providing detailed variant 
classification guidance to update the recommendations on 
interpretations of sequence variants previously provided 
by the ACMG. The Canadian Open Genetics Repository 
is an endeavor aims to establish collaboration of Canadian 
laboratories with other countries to support the 
development of tools for sharing laboratory data in 
addition to the collection, storage, sharing and robust 
analysis of variants in the laboratories across Canada 
[102]. There are other initiatives have been established to 
ensure data security and privacy through standardization. 
For instance, a framework is established that provides 
guidance for responsible sharing of genomic and health-
related data including personal data [103]. The Minimum 
Information About a Microarray Experiment (MIAME) 
[104] provides guidelines for the minimum information to 
describe the experiment details of DNA microarray data 
so that the experiment could either be reproduced or 
analyzed the data de novo [105]. Similarly, data modeling 
and XML-based exchange standards ‘Microarray Gene 
Expression’ appeared in the form of Object Model 
(MAGE-OM), Markup Language (MAGE-ML) [106], 
and a Controlled Vocabulary called the MGED Ontology 
[107]. These standards resulted the creation and evolution 
of a several interoperable databases and repositories [105]. 
For seamless integration and information exchange, 
recently Health Level Seven (HL7) extended the efforts on 
Genomic data working group with its newly invented 
popular standard called Fast Health Interoperability 
Resource (FHIR) [108], [109]. One of the main FHIR 
resources is a Sequence resource which is designed to 
describe an atomic sequence containing the alignment 
sequencing test result and multiple variations [110]. For 
the facilitation of standardized clinic-genomics apps, a 
framework called Substitutable Medical Applications & 
Reusable Technologies (SMART) on FHIR Genomics is 
developed which specifies genomic variant data resource 
definitions [111]. SMART on FHIR Genomics 
specification offers developers a unified framework to 
work with multiple resources of genomic and clinical data 
to facilitate the type of apps required for precision 
medicine. A brief summary of pertinent initiatives on 
standardization in the area of PM is provided in Table V. 
TABLE V 
CLASSIFICATION OF STANDARD INITIATIVES IN THE DOMAIN OF PRECISION MEDICINE 
Initiative 
Name 
Year Standard Body Scope 
Biosharing 
[100] 
2011 FAIRsharing 
team, Oxford 
e-Research 
Center. 
Integration 
and Exchange 
MIAME 
[104] 
2001 FGED-
Functional 
Genomics 
Data Society 
SMART 
on FHIR 
Genomics 
[109] 
2015 HL7 ® 
International 
PMI Data 
Security 
Principles 
Guide 
[112][113] 
- ONC – Office 
of the National 
Coordinator 
for Health 
Information 
Technology 
Privacy and 
Security 
PMI-
AURP 
[114] 
2016 GSWG 
HGNC 
database 
[115] 
2007 HUGO 
Vocabulary 
and/or 
Nomenclature 
UMLS ® 
[116] 
- U.S. National 
Library of 
Medicine 
(NIH) 
 
D. Summary and Insight 
At a granular detailed level, there exist a lot of 
implementation challenges that are highlighted in various 
studies ranging from genotype data preprocessing, 
mapping and alignments, unstructured clinical text 
processing, image processing and environmental data 
acquisition and synchronization. In this section, we 
focused on generalized implementation challenges that 
exist irrespective of individuals' realizations of PM. The 
challenges are mostly related to the rethinking on a new 
design for the clinical decision support systems to include 
information from the other aspects of PM – molecular, -
omic and environmental in order to produce the right 
decision for the right patient. We included the designs in 
the existing studies and provided the abstract 
representation of an ecosystem of PM for enhancing the 
design of existing electronic health record systems with 
genome. We deliberated the integration challenges at data 
and process levels and the standardization efforts at global 
spectrum. 
VII.  PM Global Initiatives 
PM is spreading globally with a fast pace and is thereby 
creating a multibillion market. According to a report 
issued by Persistence Market Research, global PM market 
is expected to approach $ 172.95 Billion by the end of 
2024 [117], [118]. Different countries share this market by 
initiating innovative projects to support PM in terms of 
establishing infrastructure, research centers, working 
groups, and standardization bodies. Different countries 
allocated different sort and amount of funding to support 
the PM initiative. In this section, we briefly elaborate 
country-wise initiatives with their goals and way of 
working. 
A. United States 
United States of America took the lead launching the idea 
of Precision Medicine under the Obama administration 
back in 2015 [1]. The idea was taken further by the 
National Institutes of Health (NIH) and other partners. 
Initially, a budget of $215 million investment has been 
announced in the President’s 2016 Budget. NIH-funded 
resource ClinGen is dedicated to constructing an 
authoritative central resource  to establish clinical 
relevance of genes and variants for the convenient use in 
precision medicine and research [119][120]. Ensuring the 
accuracy of NGS tests, US FDA is working on three 
aspects; guidance for Databases to allow developers to use 
data from FDA-based databases of genetic variants, 
recommendations for designing, developing, and 
validating NGS tests, and support to develop 
bioinformatics tool to engage users across the world to 
experiment, share data, and test new approaches [121].  
PrecisionFDA [122] as a community platform for NGS 
assay evaluation and regulatory science exploration, has 
resulted as an outcome of FDA efforts. 
B. China 
Precision Medicine is included as part of China’s five-year 
plan with an expected investment of more than $9 billion 
for research. Among 40 countries where there are 
initiatives related to PM, China is on the top from 
investment perspective. Compared to the United States 
PMI investments, China is spending $43 for every $1 of 
US, thus making China as a global leader in PM [123]. The 
Beijing Genome Institute (BGI) [124] is the world’s 
largest genomic organization with a focus of genetic 
sequencing. Affiliated to BGI, the China National 
GeneBank [125] has over 500 million genetic sequences 
stored in more than 40 databases, as of early 2017. Sichuan 
University’s West China Hospital which is ranked the first 
among all Chinese hospitals for four consecutive years in 
science & technology influence, plans to sequence 1 
million human genomes itself [126], [127]. AliCloud by 
Alibaba Group partnered with BGI and Intel Corporations 
have launched Asia’s first cloud platform for precision 
medicine and its applications with a vision to accelerate 
the advent of precision medicine [128]. More to PM 
initiative, it is anticipated that leading institutes, including 
Fudan University, Tsinghua University, and the Chinese 
Academy of Medical Sciences, are trying to establish 
precision-medicine centres [126]. 
C. United Kingdom 
United Kingdom has started a well-known project 
‘100,000 Genomes Project’ in 2013 with a goal to 
sequence 100,000 genomes from around 70, 000 people 
from the participants of National Health Service (NHS) 
patients having a rare disease [129][130]. This project is 
considered currently as the world’s largest national 
sequencing project of its kind. A program Coordination 
Group led by Innovative UK is active in precision 
medicine to bring together representatives from UK public 
sector and charity funders and through this group, a dataset 
of over 400 infrastructure investments in precision 
medicine has already been developed [131], [132]. 
Innovate UK is envisioned to invest up to £6 million in 
precision medicine technologies related innovation 
projects [133]. Overall, the UK government has invested 
more than £1 billion in developing precision medicine 
research infrastructure [134]. 
D. Japan 
Like other countries, Japan is also contributing to support 
the development of personalized and precision medicine 
(PPM) [135]. Japan has established three biobanks to 
collect genome data; Bio Bank Japan, National Center Bio 
Bank Network, and Tohoku Medical Megabank. All these 
three banks work together, however Bio Bank Japan being 
the largest of the thee, plans to collect data from 300,000 
people alone. The total budget of $ 103 million is allocated 
in 2016 for the plans like clinical trials, research on 
genomic care, and establishing seven core hospitals to 
support the provision of genomic medical treatments 
[135]. Additionally, Japan has established the most 
successful National Cancer Genome Screening System 
(SCRUM-Japan) project under the supervision of National 
Cancer Center Hospital, Japan [136], which assists 
hospitals and pharmaceutical companies develop PPM for 
cancer. The aim of SCRUM-Japan trials is to enroll 4750 
patients with cancer in about 2 years’ plan starting in 
February 2015 and ending in March 2017 [136]. 
E. South Korea 
South Korea introduced itself with the International 
Precision Medicine Center (IPMC) as the world’s first 
Precision Medicine center focused on Cell Therapy. The 
IPMC is envisioned to take a pioneering role in 
standardization of future medicine with a focus on genome 
and bio convergence technology [137]. The Korean 
scientists are succeeded to produce a de novo genome 
assembly for a Korean individuals and the results are 
published in Nature [138]. The Korea’s biobanking 
system is currently operating a nationwide network of 17 
university-affiliated hospitals to collect bio-specimens 
from patients and then National Biobank of Korea has 
collected biological samples from some 770, 000 people 
and distributed them to 1,915 research projects which 
resulted in a total of 751 research papers as of the end of 
December 2016 [139], [140]. From industrial sector, the 
information erupted that the Syapse – a leading precision 
medicine company joined hands with Seoul National 
University Hospital (SNUH), Korea to launch a precision 
oncology program for cancer care improvement in Korea 
[141]. Moreover, the Korean National Cancer Center with 
the U.S. National Institutes of Health announced to 
establish a large-scale precision medicine cohort on cancer 
[142]. In summary, the Korean government plan is to 
invest $55.7 million in Precision Medicine until 2021 
[143].  
F. Europe 
European Union (EU) is put forwarding numerous efforts 
to promote precision medicine in the Europe region. As 
the world’s biggest public-private partnership between EU 
and the European pharmaceutical industry, the Innovative 
Medicine Initiative (IMI) facilitates collaborations 
between the stakeholders and provides grants and other 
financial support to major research projects [144]. IMI in 
phase 2 that is IMI 2 program (2014-2020), will get a total 
budget of €3.276 billion, of which €1 billion came from 
the Health theme of the EU's Seventh Framework Program 
for Research (FP7) and €1 billion came from in-kind 
contributions by EFPIA companies  [145]. According to a 
report by ZION, Europe precision medicine market is 
expected to reach approximately USD 72,800.0 Million by 
2022 [146]. Under EU’s Horizon2020 Program, 
Barcelona has started European three-dimensional (3D) 
genomics project “Multi-scale complex genomics” with a 
goal is to standardize experiments in 3D genomics and 
relevant activities like storage of data. The project is 
allocated a budget of €3 million and will be conducted 
over three years [147]. The EU funded project “PerMed”, 
where representatives from EU Member States together 
with other associated countries and stakeholders, have 
developed a European strategy framework for 
personalized medicine [6]. PerMed [148] is Coordination 
and Support Action (CSA) of 27 partners including 
European key stakeholders and decision makers to allow 
synergies, avoid duplication, and ensure maximum 
transparency preparing Europe for leading the global way 
[149]. The International Consortium for Personalized 
Medicine (ICPerMed) is a voluntary, EU Member states-
led collaboration that brings together over 30 European 
and international partners to work on coordinating and 
fostering research to develop and evaluate personalized 
medicine [150][6]. 
G. Australia 
Australia perhaps the world’s first country having center 
specializing in precision medicine for infants and your 
children which is funded at Murdoch University and have 
received $473,000 in funding from the WA Department of 
Health [151]. Precision medicine has the potential to 
transform Australia’s health care system as described in a 
report released by the Australian Council of Learning 
Academies (ACOLA) [152]. ACOLA has started a project 
on precision medicine with a goal to explore the current 
trends in precision medicine technologies and a broader 
implementation in the Australian context. In the ACOLA 
detailed report, there are 12 potential areas are highlighted 
where precision medicine is likely to show significant 
impact in the next five to ten years [153]. Australian 
Genomics is a national network of clinicians, researchers, 
and diagnostic geneticists and is made up of more than 70 
partners organizations with a vision to integrate genomic 
medicine into healthcare across Australia [154]. National 
Health and Medical Research Council’s (NHMRC) 
awarded a $25 million grant in 2015 to Australian 
Genomics for a targeted Call for Research into Preparing 
Australia for the Genomics Revolution in Healthcare. 
Precision Medicine is largely endorsed by other parts of 
the world such as African, Middle East, and others Asian 
countries in their own capacity and scope. Orion Health 
Canada, for instance, has developed a care coordination 
tool that allows patients to digitally create, update and 
share their personalized care plan as well as the clinicians 
are provided with the cognitive support to make the best 
decisions possible [155][153]. Similarly, the Precision 
Driven Health initiative (PDHI) in New Zealand is 
contributing to the growing body of international research 
to enable the practice of the precision medicine while 
including genetic data, as well as information from 
exogenous sources such as an individual's diet and social 
circumstances [156].  
A wide array of international initiatives and consortiums 
have established to form guidelines for the responsible and 
homogeneous approach to data movement from one place 
to another place [5].  For instance, the Global Alliance for 
Genomic and Health (GA4GH) is meant to create 
interoperable technical standards [157].  
VIII. Future Directions 
PM is broadly welcomed around the world; the area is 
however still in its infancy and many aspects are 
untouched and mount of challenges lie ahead. It is still a 
big challenge to construct an infrastructure that entirely 
supports the prevalent sharing and effective use of health 
and genomic data in order to advance the healthcare 
system that is least reliant on on external sponsored 
resources [30]. 
A. Challenges and open questions 
Data complexity, volume, and computational challenges. The 
computational requirement of molecular and -omics data 
analysis is huge. The big data analytics is challenging 
because of multiple factors such as frequency, quality, 
dimensionality, and heterogeneity [29]. The processing 
power and memory of personal computers are usually not 
enough to process DNA sequence data for analysis and 
interpretations. To support individual researchers for their 
investigations, need cloud-based computing resources to 
share the processing power and space. The biomedical 
data complexity upsurges in dual directions: the number 
of sample and the heterogeneity [12]. These voluminous 
complex data are available in different regions of the 
world through different initiatives using -omic and 
molecular data capturing technologies which are now 
becoming faster and cheaper. The variety of available 
biological data entities for instance genes, proteins, 
metabolites, drugs, diseases, etc. are so large to manage 
through basic and simple methods. To handle, process, 
and annotate such a gigantic and diverse data is not only 
computationally intensive rather it requires significant 
computational hardware [158]. For instance, mapping of 
short reads to get 30x coverage of the human genome, 
require 13 CPU days.  Not only hardware, rather a 
comprehensive database that contains clinical, genomic 
and molecular information as much as possible. To deal 
with the high-throughput data, various method for 
dimensionality reduction in feature extraction (PCA, 
SVD, tensor-based approaches [159]) and in feature 
selection (filter-based and wrapper-based sequential 
feature selection [160]) are experimented. 
Creation of mutation databases challenge. Knowledge 
bases for example ClinVar and MyCancerGenome are still 
immature and unfinished thus raises the need to create 
custom mutation databases by different centers [11]. Also, 
there is a lack of precise annotations of variants which 
required databases to contain the curated variants and their 
interactions with potential drugs [161].  
Integration of heterogeneous data types challenge. The 
numerous data types such as omics, molecular, imaging, 
pathology, physiology, lifestyle, and clinical will be 
required to incorporated together for predictive models 
[162]. The orthogonal nature of molecular assays does not 
allow smooth analysis with clinical data, as a result, 
separate analysis is performed initially and later they are 
integrated. This kind of practice is time consuming and it 
hides the holistic view of data at one place. 
Data privacy challenge. The protection of genomic data 
from being used against employment and health 
protection, various ethical and social issues need to be 
addressed [163]. It is also required to educate public 
workforce, develop human capital and infrastructure, and 
empower the general public with correct information. 
Moreover, Cloud and Web is likely to play a huge role in 
the management of massive genomic data and the same 
time, mobile computing will be used to access those data 
which increases the privacy concerns [164]. 
B. A proposed holistic integrated precision medicine 
framework 
 
To address the unresolved challenges of PM, more 
informatics approaches are required to be designed. We 
designed a futuristic framework (Figure 8), by 
incorporating functions covering the most needed areas of 
PM implementation. The framework is a high-level 
demonstration of modules such as primary analysis, 
secondary analysis connected with knowledge 
management and data analytics that produce knowledge 
and data services respectively. These services are 
provisioned to use by different stakeholders and 
organizations including hospitals, pharmacies, and 
laboratories. The framework has also provision for 
security and privacy functions to access to the individuals’ 
data through adequate authentication, authorization, and 
access policy. 
The primary analysis module is designed to acquire 
diverse data from different input sources: clinical data, 
molecular and -omic data, sensory data, environmental 
data, and published literature data. At this stage, the data 
is preprocessed to filter-out the undesirable data items 
through the application of different natural language 
preprocessing and other statistical techniques. The 
primary analysis module utilizes the support of multiple 
tools particularly, -omic data preprocessing tools such as 
GMAP, BWA, GATK, and others.
 FIGURE 8. A holistic integrated precision medicine framework
The secondary analysis module analyzes the data received 
as an outcome from the primary analysis. Some parts of 
the data need to be integrated for combine analysis and 
other may be analyzed independently. One of the 
important activities is to find correlations among various 
data items such as among the genes as how they are related 
while studying a disease occurrence due the genes 
mutations. Similarly, it takes care of the correlation 
between genotypes and phenotypes to study the 
relationships of clinical factors and gene mutations. The 
analyzed data is stored as an internal storage for further 
processing as well as it is provided to the external entities 
as a service.  
On the top of secondary analysis, there are two modules: 
knowledge management and Data Analytics. Both 
modules utilize the analyzed data generated at the 
secondary analysis. The knowledge management module 
constructs KBs by creating, maintaining, and validating 
knowledge rules from the analyzed data. Based on this 
knowledge, various knowledge services such clinical 
decision support services can be produced. Similarly, the 
data analytics module targets to design models for 
descriptive, predictive, and prescriptive services. The 
analytical models generate data visualization services to 
present data in graphs, charts, and other statistical mode of 
presentations. 
IX. Conclusions 
Both medical professionals and informatics researchers 
across the globe have started to device computational 
infrastructural solutions to address the need of timely and 
precise decision on a patient health issue. It is a high time 
for both the informatics community and the medical 
community to collaborate with each other to make a 
combine effort for achieving the common goal of a better-
quality patient care. In this study, we elaborated the major 
areas of research and development for the realization of 
PM in the perspective of informatics. The study provides 
a fair attention to cover the important aspects and 
requirements to establish the PM program. We explained 
the need of coexistence of EBM and PM by bridging the 
gap between them. To understand the informatics 
viewpoint of how the PM is implemented, we provided an 
overview of enabling tools and techniques in three 
potential areas: biomedical informatics, clinical 
informatics, and participatory health informatics. For a 
deeper understanding of PM, the paper offers a broad view 
on how AI and big data become an integral part of PM. 
We also associated the IoT paradigm with PM and 
uncovers various advantages of integrating the two 
approaches. In addition, this paper highlights some of the 
major implementation challenges in terms of 
computational tools, data integration, security, 
standardization, and overall infrastructural solutions that 
are required to implement PM. Finally, we proposed an 
integrated holistic framework for PM to overcome the 
existing limitations. In summary, the outcomes of this 
study are expected to be beneficial for the researchers and 
professionals working in the area of medical informatics. 
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